Novaremed Ltd.
Records under this name other than the patents Novaremed Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 9 of 9 · Back to Novaremed Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,802,734 | Method of Treating or Preventing Pain Lapsed on the fee record Ended Aug 12, 2026 · Medium confidence | Lapsed on the fee record | Ended Aug 12, 2026 | Medium confidence |
| US 8,252,843 | Compounds for the treatment of AIDS and other viral diseases Lapsed on the fee record Ended Aug 28, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 28, 2024 | From the USPTO record |
| US 9,199,917 | N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation Lapsed on the fee record Ended Dec 1, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 1, 2023 | From the USPTO record |
| US 9,133,103 | N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders Lapsed on the fee record Ended Sep 15, 2023 · From the USPTO record | Lapsed on the fee record | Ended Sep 15, 2023 | From the USPTO record |
| US 8,309,606 | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection Term ended Term ended Aug 18, 2023 · From the USPTO record | Term ended | Term ended Aug 18, 2023 | From the USPTO record |
| US 8,883,853 | N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation Lapsed on the fee record Ended Nov 11, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 11, 2022 | From the USPTO record |
| US 7,754,771 | Compounds for the treatment of AIDS and other viral diseases Lapsed on the fee record Ended Jul 13, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 13, 2022 | From the USPTO record |
| US 7,674,829 | Compounds for the treatment of AIDS and other viral diseases Lapsed on the fee record Ended Mar 9, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 9, 2022 | From the USPTO record |
| US 7,642,290 | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection Lapsed on the fee record Ended Jan 5, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jan 5, 2022 | From the USPTO record |